NNM Securities

COMPANY
more from company profile
HomeMarket Info Company Profile Smart Quotes

Smart Quotes

AJANTA PHARMA LTD.

NSE : AJANTPHARMBSE : 532331ISIN CODE : INE031B01049Industry : Pharmaceuticals & DrugsHouse : Vimal Agrawal
BSE2200.7062.85 (+2.94 %)
PREV CLOSE ( ) 2137.85
OPEN PRICE ( ) 2159.95
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 6466
TODAY'S LOW / HIGH ( )2120.85 2280.00
52 WK LOW / HIGH ( )1240.55 2355.05
NSE2193.5053.55 (+2.5 %)
PREV CLOSE( ) 2139.95
OPEN PRICE ( ) 2144.00
BID PRICE (QTY) 2193.50 (2970)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 205252
TODAY'S LOW / HIGH( ) 2120.00 2286.95
52 WK LOW / HIGH ( )1246.75 2353.95
BSE
1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Incorporation Year : 31-12 1979
Management Info
Mannalal B Agrawal - Chairman Yogesh M Agrawal - Managing Director
Registered Office

Address Ajanta House,Charkop ,Kandivali (W),
Mumbai,
Maharashtra-400067

Phone 022-66061000

Email legal.info@ajantapharma.com

Website www.ajantapharma.com

Registrars Details
Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE, MCX
NEWS
26Apr Buy Back Offer
 Buy Back of Shares & Quarterly Results & Audited Results
15Apr Ajanta Pharma informs about compliance
Ajanta Pharma has informed that it enclosed Compliance Certificate - Reg..
30Mar Ajanta Pharma informs about disclosure
Ajanta Pharma has informed that the exchange has received Disclosure und..
31Jan Cancellation Of Employee Stock Option
Please note that the Nomination and Remuneration Committee of the Board..
25Jan Ajanta Pharma informs about update on
With reference to its letter dated 19th January 2024, informing about th..
MORE
Financials
Rs. in Millions
QTR Dec 23 ANNUAL 23
Net Profit2201.55587.19999999999
Gross Profit 3051.4 6998.49999999999
Operating Profit 3409.18320.29999999999
Net Sales 10852.934112.7
MORE
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group
Divi's Lab (BSE)
 4025.35 (4.81%)
M.Cap (Rs. in Cr)106860.39
Sanofi India (BSE)
 8278.10 (1.76%)
M.Cap (Rs. in Cr)19064.98
Abbott India (BSE)
 25864.85 (0.54%)
M.Cap (Rs. in Cr)54961.00
Astrazeneca Pharma I (BSE)
 5415.40 (2.18%)
M.Cap (Rs. in Cr)13538.50
Glaxosmithkline Phar (BSE)
 2132.75 (3.26%)
M.Cap (Rs. in Cr)36130.07
MORE
Shareholding Pattern
PROMOTERS 66.21%
MUTUAL FUNDS/UTI 14.76%
NON-INSTITUTION 7.76%
FI/BANKS/INSURANCE 2.16%
GOVERNMENT 0%
FII 0%
MORE
Mf Holdings
MORE
ATTENTION INVESTORSKYCIPO
TERMS & CONDITIONS| PRIVACY POLICY| REFUND & CANCELLATION POLICY| DISCLAIMER| DISCLOSURE| KMP DETAILS | CDSL e-Voting | SEBI| FMC| NSE| BSE| MCX | SCORES
Download Client Registration Documents (Rights & Obligations, Risk Disclosure Document, Do’s & Don’t’s) in Vernacular Language :
Assamese Bengali Gujrati Hindi Kanada
Kashmiri Konkani Malyalam Marathi Oriya
Punjabi Sindhi Tamil Telegu Urdu
REGISTRATION NOS.

NSE CM-INZ000234235|NSE F& O - INZ000234235, NSE CD-INZ000234235, BSE CM–INZ000234235 |BSE F & O - INZ000234235|BSE CD- INZ000234235 MCX-SX CM-INZ000234235|MCX-SX F & O - INZ000234235|MCX-SX CD-INZ000234235 NSDL - IN-DP-NSDL-319-2009ROC REG - 21-097912,CDSL : IN-DP-242-2016|SEBI-PMS: INP000007100|LEI- 3358007DLCFNHY8J2F96

Filing compliant on SCORES – Easy & quick

  • Register on SCORES portal
  • Mandatory details for filing complaints on SCORES:
    • Name
    • PAN
    • Address
    • Mobile Number
    • E-mail ID
  • Benefits:
    • i.) Effective communication
    • ii.) Speedy redressal of the grievances
SMART ODR Portal
INVESTOR PROTECTION

Compliance officer : Apurva Mittal, Tel No: 022-40790035,022-40790024, Mobile No: 9152943075, E-mail ID: compliance@nnmsecurities.com, cdsl@nnmsecurities.com

Investor grievance : support@nnmsecurities.com

"NNM Securities has partnered with TradingView for its charting technology. An investment and trading platform empowering users with global market data and analytical tools like Stock Screener and Economic Calendar."

Copyright © 2021 NNM Securities.com

Advanced Charts Technology Partner: TradingView

Designed , Developed & Content Powered by ●●● Accord Fintech Pvt. Ltd.